GCM
AGIO icon

Gladius Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Gladius Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-758
Closed -$17K – 367
2022
Q2 		$17K Buy
+758
New +$17.1K ﹤0.01% 324

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gladius Capital Management's AGIO Position: Q3 2022 in Review

Gladius Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2022, closing a stake of 758 shares — an estimated $17K sold.

Gladius Capital Management first reported a position in AGIO in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 168 funds tracked by Wall St. Rank hold AGIO as of Q3 2022.

  • Gladius Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 758 Agios Pharmaceuticals shares in Q3 2022, an estimated $17K.
  • Gladius Capital Management first reported a position in Agios Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's Agios Pharmaceuticals position peaked at $17K in Q2 2022.
  • 168 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.